A Phase I trial of the anti-IL23 monoclonal antibody tildrakizumab, in combination with abiraterone acetate, for the treatment of metastatic castration-resistant prostate cancer.

Chandran K, Guo C, Pacey S, Villacampa G, Matthews R, Prout T, Fernandes J, Turner A, Parmar M, Riisnaes R, Ferreira A, Carreira S, Bertan C, Crespo M, Figueiredo I, Yuan W, Bogdan D, Raynaud F, Ruddle R, Calì B, Maddalena M, Calcinotto A, Yap C, Sharp A, Alimonti A, De Bono J, Paschalis A

Open source

DOI: 10.1007/s10637-026-01619-x
Published: 2026 Aug
Container: Investigational new drugs
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1007/s10637-026-01619-x,
  title = {A Phase I trial of the anti-IL23 monoclonal antibody tildrakizumab, in combination with abiraterone acetate, for the treatment of metastatic castration-resistant prostate cancer.},
  author = {Chandran K and Guo C and Pacey S and Villacampa G and Matthews R and Prout T and Fernandes J and Turner A and Parmar M and Riisnaes R and Ferreira A and Carreira S and Bertan C and Crespo M and Figueiredo I and Yuan W and Bogdan D and Raynaud F and Ruddle R and Calì B and Maddalena M and Calcinotto A and Yap C and Sharp A and Alimonti A and De Bono J and Paschalis A},
  year = {2026},
  journal = {Investigational new drugs},
  doi = {10.1007/s10637-026-01619-x},
  url = {https://doi.org/10.1007/s10637-026-01619-x}
}

RIS

TY  - JOUR
TI  - A Phase I trial of the anti-IL23 monoclonal antibody tildrakizumab, in combination with abiraterone acetate, for the treatment of metastatic castration-resistant prostate cancer.
AU  - Chandran K
AU  - Guo C
AU  - Pacey S
AU  - Villacampa G
AU  - Matthews R
AU  - Prout T
AU  - Fernandes J
AU  - Turner A
AU  - Parmar M
AU  - Riisnaes R
AU  - Ferreira A
AU  - Carreira S
AU  - Bertan C
AU  - Crespo M
AU  - Figueiredo I
AU  - Yuan W
AU  - Bogdan D
AU  - Raynaud F
AU  - Ruddle R
AU  - Calì B
AU  - Maddalena M
AU  - Calcinotto A
AU  - Yap C
AU  - Sharp A
AU  - Alimonti A
AU  - De Bono J
AU  - Paschalis A
PY  - 2026
JO  - Investigational new drugs
DO  - 10.1007/s10637-026-01619-x
UR  - https://doi.org/10.1007/s10637-026-01619-x
ER  -

APA

K, C., C, G., S, P., G, V., R, M., T, P., J, F., A, T., M, P., R, R., A, F., S, C., C, B., M, C., I, F., W, Y., D, B., F, R., R, R., B, C., M, M., A, C., C, Y., A, S., A, A., J, D. B., & A, P. (2026). A Phase I trial of the anti-IL23 monoclonal antibody tildrakizumab, in combination with abiraterone acetate, for the treatment of metastatic castration-resistant prostate cancer.. Investigational new drugs. https://doi.org/10.1007/s10637-026-01619-x

Source records

pubmed · retrieved 2026-09-26T22:42:18.147Z
europe-pmc · retrieved 2026-09-26T22:42:18.158Z